Literature DB >> 22015067

[Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report].

I De Monchy1, A Labbé, N Pogorzalek, G Gendron, M M'Garrech, G Kaswin, M Labetoulle.   

Abstract

Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane transplantation may also be used in severe cases, but their cost and safety are still under debate. We report a case of a patient with a history of herpes zoster ophthalmicus, who developed a persistent epithelial ulcer after cataract surgery, with no improvement despite 3 weeks of artificial tears (eight drops per day). A new ophthalmologic solution based on a regenerating agent (RGTA, Cacicol20(®)) was then used, with a dosage of two eye drops per week for 6 weeks. Improvement was observed 1 week later, and complete healing was obtained in less than 3 weeks, with no side effects. This heparin mimetic, which may stimulate extracellular matrix healing, may be a possible alternative therapy to autologous serum or amniotic membrane transplantation in severe neurotrophic ulcer. However, randomized studies are necessary to validate this observation. Copyright Â
© 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015067     DOI: 10.1016/j.jfo.2011.09.002

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  6 in total

1.  Matrix regeneration agents improve wound healing in non-stressed human corneal epithelial cells.

Authors:  A Robciuc; R P J Arvola; M Jauhiainen; J M Holopainen
Journal:  Eye (Lond)       Date:  2017-12-22       Impact factor: 3.775

2.  Corneal matrix repair therapy with the regenerating agent in neurotrophic persistent epithelial defects.

Authors:  Canan Asli Utine; Ceren Engin Durmaz; Nilufer Koçak
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

3.  Treatment of Acanthamoeba neurotrophic corneal ulcer with topical matrix therapy.

Authors:  Antonio Mateo; Beatriz Abadía; Pilar Calvo; Enrique Minguez; Luis Pablo; José Manuel Benitez Del Castillo
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-06-21

Review 4.  RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients.

Authors:  Denis Barritault; Marie Gilbert-Sirieix; Kim Lee Rice; Fernando Siñeriz; Dulce Papy-Garcia; Christophe Baudouin; Pascal Desgranges; Gilbert Zakine; Jean-Louis Saffar; Johan van Neck
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

5.  Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs.

Authors:  Jessica A Martinez; Franck Chiappini; Denis Barritault
Journal:  Vet Sci       Date:  2019-12-13

6.  A Rapid Response to Matrix Therapy With RGTA in Severe Epidermolysis Bullosa.

Authors:  Ali Al Malaq; Denis Barritault
Journal:  Eplasty       Date:  2012-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.